Need help with ordering? Contact us at 1-877-468-3832
Economic considerations for your clinic (July 18, 2017)
Tools to evaluate the financial implications to your clients and your practice
Craig Clifford, DVM, MS, DACVIM (Oncology)

Tanovea-CA1 is Available for Purchase in all 50 US states

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.

Important Safety Information: TANOVEA-CA1 is indicated for the treatment of lymphoma in dogs. In clinical trials, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA-CA1. Do not use in West Highland White Terriers and use with caution in other terrier breeds. Owners should take extra care when handling and cleaning up after their dog for five days after treatment. Please see the package insert for full prescribing information, warnings and precautions.